Bosutinib is an antineoplastic agent used for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adults with inadequate clinical response to other treatments. Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML.
- Mechanism
- Curator reviewed · 1 reference
Bosutinib is a tyrosine kinase inhibitor. Bosutinib inhibits the BCR-ABL kinase that promotes CML; it is also an inhibitor of Src-family kinases including Src, Lyn, and Hck. Bosutinib inhibited 16 of 18 imatinib-resistant forms of BCR-ABL kinase expressed in murine myeloid cell lines. Bosutinib did not inhibit the T315I and V299L mutant cells.
- Primary indication
- Bosutinib is indicated for the treatment of adult and pediatric patients 1 year of age and older with chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia that is newly diagnosed or resistant or intolerant to prior...Curator reviewed · 4 structured indications
- Formula / weight
- C26H29Cl2N5O3 · 530.446 g/mol (avg)
- First approval
- Canada, 2014 · United States, 2012 · European Union, 2022
- Code names
- SK-606 · SKI-606
- Brand names
Resolves to
UBPYILGKFZZVDX-UHFFFAOYSA-NSMILESCOC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1ClWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Bosutinib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account